Jetrea Side Effects
Generic name: ocriplasmin ophthalmic
Medically reviewed by Drugs.com. Last updated on Aug 29, 2023.
Note: This document contains side effect information about ocriplasmin ophthalmic. Some dosage forms listed on this page may not apply to the brand name Jetrea.
Applies to ocriplasmin ophthalmic: parenteral injection.
Side effects include:
Vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, retinal edema.
For Healthcare Professionals
Applies to ocriplasmin ophthalmic: intravitreal solution.
The most commonly reported side effects included vitreous floaters, eye pain, photopsia, and blurred vision.[Ref]
Very common (10% or more): Vitreous floaters (up to 16.8%), macular hole (up to 15.8%), eye pain (up to 13.1%), photopsia (up to 11.8%), chromatopsia, conjunctival hemorrhage
Common (1% to 10%): Abnormal optical coherence tomography (OCT), anterior chamber cell, anterior chamber flare, blurred vision, conjunctival edema, conjunctival hyperemia, cystoid macular edema, decreased best corrected visual acuity (BCVA), dry eye, dyschromatopsia, eye irritation, eye pruritus, eyelid edema, foreign body sensation in eyes, increased intraocular pressure, increased lacrimation, iritis, macular degeneration, macular edema, metamorphopsia, ocular discomfort, ocular hyperemia, photophobia, photopsia, reduced visual acuity, retinal breaks, retinal degeneration, retinal edema, retinal hemorrhage, retinal pigment epitheliopathy, subretinal fluid, visual impairment, vitreous detachment, vitreous hemorrhage, vitritis
Uncommon (0.1% to 1%): Anterior chamber inflammation, conjunctival irritation, corneal abrasion, diplopia, eye inflammation, hyphema, lens subluxation, miosis, night blindness, retinal detachment, retinal tear, serious acute visual impairment, severe acute visual impairment, transient blindness, unequal pupils
Frequency not reported: Dim vision, macular hole progression
Postmarketing reports: Impaired pupillary reflex[Ref]
Very common (10% or more): Abnormal color vision test, abnormal retinogram
Common (1% to 10%): Abnormal macular reflex, increased intraocular pressure, visual field defect, visual symptoms perceived in the contralateral eye
Frequency not reported: Scotoma[Ref]
Common (1% to 10%): Intravitreal injection procedure associated effects[Ref]
Frequency not reported: Immunogenicity[Ref]
More about Jetrea (ocriplasmin ophthalmic)
- Compare alternatives
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous ophthalmic agents
Related treatment guides
1. Cerner Multum, Inc. UK Summary of Product Characteristics.
2. Cerner Multum, Inc. Australian Product Information.
3. Product Information. Jetrea (ocriplasmin ophthalmic). ThromboGenics Inc. 2012.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.